我院2006-2010年抗糖尿病药物应用分析

目的:分析北京医院抗糖尿病药的应用情况,为临床合理用药提供参考。方法:对卫生部北京医院2006–2010年抗糖尿病药物的种类、用量、销售金额、用药频度、日均费用等进行分析。结果:我院口服抗糖尿病药的销售金额占抗糖尿病药总金额的70%,其中,以α-葡萄糖苷酶抑制剂所占比例最高,胰岛素类约占30%;阿卡波糖、二甲双胍、诺和灵30R的DDDs较高,临床较为常用;二甲双胍、格列美脲、格列喹酮的DDC较低;噻唑烷二酮类药物的销售金额和DDDs逐年下降,其他药品的销售金额和DDDs均呈上升趋势,DDC逐年下降。瑞格列奈、那格列奈、甘精胰岛素的排序比值较低。结论:我院2006–2010年抗糖尿病药物的使用品种相对稳定,基本满足临床安全、经济、有效用药的需求。

Utilization analysis of anti-diabetic drugs in our hospital during 2006-2010

Objective： To analyze the application situation of antidiabetic drugs in our hospital to provide reference for clinical rational drug use. Methods： The variety, amount, consumption sum, DDDs and average daily cost of antidiabetic drugs used in our hospital during 2006 - 2010 were analyzed retrospectively. Results： Sales amount of oral antidiabetic drugs accounted for 70% of the total amount of antidiabetic drugs. The sales amount of a-glucosidase inhibitor was the largest and the sales amount of insulin accounted for about 30% of the total amount of antidiabetic drugs. The values of DDDs of acarbose, metformin and Novolin 30R were higher than that of other antidiabetic drugs due to more common use in clinic. The values of DDC of metformin, glimepiride,gliquidone were lower. Exception for the decrease in the sales amount and DDDs of thiazolidinediones, the sales amount and DDDs of other antidiabetic drugs showed an upward trend. The ratios of consumption sum sequence to DDDs sequence of repaglinide, nateglinide and the insulin glargine were smaller. Conclusion： The oral antidiabetic drugs used in our hospital during 2006 - 2010 were basically stable in respect of varieties, which could meet the needs of rational drug use.